Sales & Earnings In Brief: Nestle, NBTY, DSM, Vitamin Shoppe, Mannatech And More
This article was originally published in The Tan Sheet
Executive Summary
Nestle builds on infant nutrition; NBTY facility restructuring continues; DSM counts on organic nutrition growth; Vitamin Shoppe comp store growth slows; Omega Protein gains from fish oil yields; Vitacost deemphasizes supplement sales; Mannatech makes headway in Asia; LunaRich dominates Reliv sales.
You may also be interested in...
Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio
Nestle’s $11.85 billion acquisition of Pfizer’s pediatric nutritionals business came in above or at the upper end of most analysts’ expectations. With the deal, Nestle keeps the portfolio – projected to generate $2.4 billion in 2012 sales – away from rivals Danone and Mead Johnson.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.